Introduction {#Sec1}
============

Disturbances in inhibitory control over behaviour play a central role in the symptomatology of attention deficit/hyperactivity disorder (ADHD; Barkley [@CR11]; Sonuga-Barke [@CR65]). Neuroimaging studies have greatly contributed to our growing understanding of the neural substrates of inhibitory response control processes (Aron and Poldrack [@CR4]) and the observed structural and functional changes in the brains of ADHD patients (Valera et al. [@CR68]). In addition to human preclinical approaches, much of our understanding of the neural substrates of inhibitory response control is derived from rodent lesion and neuropharmacological studies (Eagle et al. [@CR25]; Pattij and Vanderschuren [@CR47]; Winstanley et al. [@CR73]).

Consistent with the therapeutic efficacy of the noradrenaline (NA) transporter inhibitor atomoxetine in ADHD patients (Chamberlain et al. [@CR19]), recent studies have demonstrated that atomoxetine also improves inhibitory response control in several translational rodent models (Bari et al. [@CR10]; Blondeau and Dellu-Hagedorn [@CR15]; Robinson et al. [@CR54]). Thus, these findings implicate noradrenergic neurotransmission in modulating inhibitory response control processes, although the precise mechanisms underlying these effects are not fully understood. Early neuronal recording experiments and subsequent studies in laboratory animals have shown that NA neurons of the locus coeruleus (LC) are phasically discharged upon exposure to novel, salient and arousing environmental stimuli (see for example, Aston-Jones and Bloom [@CR5]; Foote et al. [@CR27]; Sara et al. [@CR60]). This phasic activity of the LC NA system might promote processing of these stimuli in upstream projection areas, including cortical areas, and thereby facilitate the preparation of subsequent appropriate behavioural responses. In addition, moderate tonic activity of the LC has been associated with optimal behavioural performance (Aston-Jones et al. [@CR7]). In the rodent brain, frontal cortical areas importantly modulate inhibitory response control processes (Chudasama et al. [@CR21]) and furthermore receive afferent projections from the LC (for review see, Foote and Morrison [@CR26]). In turn, frontal cortical areas might modulate activity of the LC via efferent projections (Jodo et al. [@CR33]; Sara and Herve-Minvielle [@CR59]). Collectively, this has led to the view that the NA system---perhaps acting in concert with the dopaminergic system---plays a key role in optimizing behavioural responses including prefrontal cortical and executive cognitive function (Arnsten [@CR1]; Aston-Jones and Cohen [@CR6]; Sara [@CR58]). Considering the current working hypothesis on noradrenergic functioning, this might also explain the therapeutic efficacy of methylphenidate in ADHD, which has been shown to enhance NA levels at low doses (Berridge et al. [@CR14]; Devilbiss and Berridge [@CR24]).

To date, little is known with regard to the involvement of different adrenoceptor subtypes in inhibitory response control, although previous work in rodents suggested a functional role of α-adrenoceptors (Milstein et al. [@CR39]; Puumala et al. [@CR50]; Ruotsalainen et al. [@CR56]; Sirvio et al. [@CR64]). Generally, these studies suggest α1-adrenoceptor involvement, as an agonist of this adrenoceptor subtype was found to selectively improve inhibitory response control (Puumala et al. [@CR50]). Moreover, α2-adrenoceptor agonists also ameliorate inhibitory response control, albeit these beneficial effects were only observed at doses that simultaneously impaired somatomotor performance (Milstein et al. [@CR39]; Ruotsalainen et al. [@CR56]; Sirvio et al. [@CR64]). Thus, these preclinical findings with α-adrenoceptor agonists in part support the clinical beneficial effects of the α2-adrenoceptor agonists clonidine and guanfacine in ADHD (Arnsten et al. [@CR3]). Interestingly, in both healthy volunteers and rats, the α2-adrenoceptor antagonist yohimbine has been demonstrated to impair inhibitory response control (Sun et al. [@CR66]; Swann et al. [@CR67]). To our knowledge, β-adrenoceptor involvement in inhibitory response control has not been investigated in detail before. Therefore, further dissecting the contribution of specific adrenoceptors therein could provide novel insights into the mechanism of action of atomoxetine and methylphenidate. To that end, we investigated the effects of various selective α-adrenoceptor and β-adrenoceptor agonists in addition to those of indirect agonists on inhibitory response control in rats. More specifically, we tested the effects of the monoamine reuptake inhibitor methylphenidate, the noradrenaline reuptake inhibitor desipramine, the α1-adrenoceptor and α2-adrenoceptor agonists phenylephrine and clonidine, the non-selective β-adrenoceptor agonist isoprenaline and lastly the β1-adrenoceptor and β2-adrenoceptor agonists, dobutamine and clenbuterol. To assess drug effects, rats were trained in the 5-choice serial reaction time task (5CSRTT), which is a widely employed rodent operant cognitive task adopted from the human continuous performance task that measures aspects of visuospatial attention as well as inhibitory response control (see for reviews, Bari et al. [@CR9]; Robbins [@CR53]).

Material and methods {#Sec2}
====================

Subjects {#Sec3}
--------

In total, 60 male Wistar rats were obtained from Harlan CPB (Horst, The Netherlands). At the start of the experiments, animals were 12 weeks old, weighed approximately 250 g and were housed in pairs in macrolon cages (42.5 × 26.6 × 18.5 cm; *l* × *w* × *h*) under a reversed 12-h light/dark cycle (lights on at 7:00 p.m.) at controlled room temperature (21 ± 2°C) and relative humidity of 60 ± 15%. Animals were maintained at approximately 90% of their free-feeding weight, starting 1 week prior to the beginning of the experiments by restricting the amount of standard rodent food pellets (Harlan Teklad Global Diet, Blackthorn, UK). Water was available ad libitum throughout the entire experiment. All experiments were conducted with the approval of the animal ethical committee of the Vrije Universiteit, Amsterdam, the Netherlands.

Apparatus {#Sec4}
---------

Experiments were conducted in identical rat five hole nose poke operant chambers with stainless steel grid floors (MED-NPW-5L, Med Associates Inc., St. Albans, VT, USA) housed in sound-insulating and ventilated cubicles. Set in the curved wall of each box was an array of five holes. Each nose poke unit was equipped with an infrared detector and a yellow light emitting diode stimulus light. Rodent food pellets (45 mg, Formula P, Bio-Serv, Frenchtown, USA) could be delivered at the opposite wall via a dispenser and a white house light could illuminate the chamber. A computer equipped with MED-PC version 1.17 (Med Associates Inc.) controlled experimental sessions and recorded data. The animals were tested once daily from Monday until Friday during the dark phase of the light/dark cycle.

Behavioural procedure {#Sec5}
---------------------

To habituate animals to the operant chambers, rats were exposed to the operant chambers for 20 min with the houselight on and the food cup containing three food pellets for two consecutive sessions. Subsequently, in the next two sessions, pellets (100 per session) were delivered with an average delay of 15 s to allow the animals to associate the sound of pellet delivery with reward. Following this, the rats were trained in the 5CSRTT paradigm. A detailed description of the 5CSRTT behavioural procedure in our laboratory has been provided previously (Van Gaalen et al. [@CR70]). In short, rats were trained to detect and respond to a brief visual stimulus in one of five nose poke units in order to obtain a food reward. Each session terminated after 100 trials or 30 min, whichever occurred first. Initially, the duration of this stimulus was 32 s and was gradually decreased to 1 s over sessions until animals reached stable baseline performance (accuracy \>80% correct choice and \<20% errors of omission, for at least five consecutive sessions). Responding during stimulus presentation or within the limited hold (LH) period of 2 s was counted as a correct response. Incorrect, premature responses during the fixed 5-s intertrial interval and errors of omission (no responses or a response after the LH) did not lead to the delivery of a food reward and resulted in a 5-s time out period during which the houselight was extinguished, whereas perseverative responses, i.e. repeated responding during the presentation of the stimulus, were measured but did not have any programmed consequences. Two different measures of inhibitory control were measured, namely (1) the percentage of premature responses before stimulus onset, calculated as $\documentclass[12pt]{minimal}
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Drugs {#Sec6}
-----

Methylphenidate hydrochloride (Fagron, Nieuwerkerk a/d IJssel, Netherlands), clenbuterol hydrochloride, desipramine hydrochloride, dobutamine hydrochloride, phenylephrine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA), clonidine hydrochloride (Boehringer Ingelheim, Ingelheim am Rhein, Germany) and isoprenaline sulphate (ACF Chemiefarma, Maarssen, the Netherlands) were dissolved in sterile saline. All drugs were injected 30 min before testing, with the exception of methylphenidate, isoprenaline and clenbuterol that were injected 20 min before testing. Desipramine (dose range, 1--10 mg/kg), clenbuterol (dose range, 0.01--0.1 mg/kg), dobutamine (dose range, 1--6 mg/kg) and phenylephrine (dose range, 0.3--3 mg/kg) were injected intraperitoneally, clonidine (dose range, 0.01--0.03 mg/kg) and isoprenaline (dose range, 0.1--1 mg/kg) were injected subcutaneously and methylphenidate (dose range, 1--10 mg/kg) was administered orally via oral gavage. In group 1 (*n* = 14), the order of testing drugs was (1) desipramine, (2) clonidine and (3) phenylephrine. In group 2 (*n* = 14), isoprenaline was tested; in group 3 (*n* = 16), methylphenidate was tested, and in group 4 (*n* = 16), dobutamine and clenbuterol were tested. Drugs were freshly prepared before testing and injected in a volume of 1 ml/kg body weight according to a Latin square within-subjects design on Tuesdays and Fridays with baseline training sessions on the other weekdays. Drug doses were based on previous reports employing instrumental behaviour paradigms (Arnsten and Dudley [@CR2]; Munzar and Goldberg [@CR42]; O'Donnell [@CR44]; Van Gaalen et al. [@CR71]).

Statistical analyses {#Sec7}
--------------------

Data were subjected to repeated measures analysis of variance (ANOVA) with drug dose as within-subjects variable using the Statistical Package for the Social Sciences version 14 (SPSS Inc., Chicago, IL, USA). The homogeneity of variance across groups was determined using Mauchly's tests for equal variances and in case of violation of homogeneity, Huynh--Feldt epsilon (*ε*) adjusted degrees of freedom were applied and the resulting more conservative probability values were depicted and used for subsequent analyses. In case of statistically significant main effects, further post hoc comparisons were conducted using Newman--Keuls multiple comparison tests. The level of probability for statistically significant effects was set at 0.05.

Results {#Sec8}
=======

Baseline performance {#Sec9}
--------------------

Drug testing commenced upon stable baseline performance in the 5CSRTT. Repeated measures ANOVA of the five last baseline training sessions revealed that in all groups behavioural performance had stabilized before drug testing in terms of the percentage of accurate choice \[group 1, *F*(4,52) = 1.40, *p* = 0.25; group 2, *F*(4,52) = 0.33, *p* = 0.85; group 3, *F*(4,60) = 0.63, *ε* = 0.43, *p* = 0.52; group 4, *F*(4,60) = 1.25, *p* = 0.30\], the percentage of omission errors \[group 1, *F*(4,52) = 1.37, *p* = 0.26; group 2, *F*(4,52) = 2.06, *ε* = 0.71, *p* = 0.12; group 3, *F*(4,60) = 0.65, *p* = 0.63; group 4, *F*(4,60) = 1.01, *ε* = 0.78, *p* = 0.40\] and the percentage of premature responding \[group 1, *F*(4,52) = 1.14, *p* = 0.35; group 2, *F*(4,52) = 0.30, *ε* = 0.60, *p* = 0.75; group 3, *F*(4,60) = 1.06, *ε* = 0.59, *p* = 0.37; group 4, *F*(4,60) = 1.79, *ε* = 0.59, *p* = 0.18\]. Furthermore, during testing of all separate drugs, repeated measures ANOVA on the intervening pre-drug baseline training sessions revealed that behavioural performance on accurate choice, percentage omissions and percentage premature responding did not shift and remained stable (all *p* \> 0.05; data not shown).

Methylphenidate {#Sec10}
---------------

Methylphenidate had a biphasic effect on the percentage premature responses \[Fig. [1a](#Fig1){ref-type="fig"}; *F*(3,45) = 15.72, *ε* = 0.47, *p* \< 0.001\] and strongly tended to decrease premature responding at the low dose (1 mg/kg; *p* = 0.055), whereas it increased this parameter at the highest dose (10 mg/kg; *p* = 0.002) compared to vehicle. Accurate choice was decreased by methylphenidate \[Fig. [1b](#Fig1){ref-type="fig"}; *F*(3,45) = 5.33, *p* = 0.003\], and methylphenidate also speeded correct response latencies \[Fig. [1c](#Fig1){ref-type="fig"}; *F*(3,45) = 3.28, *p* = 0.029\]. Further comparisons revealed that only 10 mg/kg methylphenidate impaired visuospatial attention (*p* = 0.001) and speeded response latencies (*p* = 0.035) compared to the vehicle. The percentage of omissions was not altered by methylphenidate \[Fig. [1d](#Fig1){ref-type="fig"}; *F*(3,45) = 0.63, *p* = 0.60\] or was the percentage of perseverative responses and latency to collect reward after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(3,45) = 0.61, *ε* = 0.53, *p* = 0.51 and *F*(3,45) = 0.40, *ε* = 0.73, *p* = 0.69, respectively\]. Fig. 1Methylphenidate exerts a bimodal effect on the percentage premature responses (**a**), decreases the percentage correct choice (**b**), shortens correct response latency (**c**) and does not affect the percentage omissions (**d**) in the 5CSRTT. All data are expressed as mean±SEM. \**p* \< 0.05 and \*\**p* \< 0.005 compared to vehicle treatmentTable 1Effects of indirect and direct adrenoceptor agonists on the percentage of perseverative responses and latencies to collect food reward after correct choiceDrugDose (mg/kg)Perseverative responses (%)Feeder latency (s)Methylphenidate03.81 ± 1.160.90 ± 0.041.03.69 ± 1.130.92 ± 0.053.05.69 ± 1.630.94 ± 0.0610.05.12 ± 2.230.88 ± 0.06Desipramine06.64 ± 1.500.99 ± 0.071.09.00 ± 2.261.23 ± 0.15\*3.08.93 ± 1.381.06 ± 0.0610.09.86 ± 1.611.25 ± 0.12\*Phenylephrine07.43 ± 1.480.98 ± 0.070.37.50 ± 1.731.08 ± 0.161.010.21 ± 2.230.91 ± 0.043.07.36 ± 1.581.15 ± 0.10Clonidine09.21 ± 2.251.09 ± 0.100.19.86 ± 2.411.36 ± 0.220.34.21 ± 0.71\*1.19 ± 0.06Isoprenaline05.29 ± 2.530.98 ± 0.050.12.64 ± 0.841.10 ± 0.070.34.21 ± 1.441.07 ± 0.051.04.57 ± 2.081.19 ± 0.08\*Dobutamine012.54 ± 7.241.21 ± 0.131.09.23 ± 4.101.31 ± 0.123.08.08 ± 2.701.16 ± 0.116.04.77 ± 1.671.25 ± 0.13Clenbuterol07.53 ± 2.141.27 ± 0.160.017.07 ± 1.751.33 ± 0.140.038.60 ± 1.651.45 ± 0.130.16.40 ± 1.391.82 ± 0.25Drug doses are expressed in milligrams per kilogram and all data are expressed as the mean±SEM\**p* \< 0.05; \*\**p* \< 0.005 versus vehicle

Desipramine {#Sec11}
-----------

The selective NA reuptake inhibitor desipramine dose dependently decreased the percentage of premature responses \[Fig. [2a](#Fig2){ref-type="fig"}; *F*(3,39) = 8.51, *p* \< 0.001\] and further analyses revealed that compared to vehicle this was the case for both the 3 and 10 mg/kg dose of desipramine (*p* = 0.022 and *p* \< 0.001, respectively). In addition to the effects of desipramine on premature responding, desipramine increased correct response latencies \[Fig. [2c](#Fig2){ref-type="fig"}; *F*(3,39) = 4.46, *p* = 0.009\] and the percentage of omissions \[Fig. [2d](#Fig2){ref-type="fig"}; (3,39) = 6.85, *ε* = 0.85, *p* = 0.002\]. Further analyses revealed that only 10 mg/kg desipramine significantly increased response latencies and omissions compared to the vehicle (*p* = 0.005 and *p* \< 0.001, respectively). Likewise, the latency to collect reward after correct choice was increased by desipramine \[Table [1](#Tab1){ref-type="table"}; *F*(3,39) = 3.37, *ε* = 0.79, *p* = 0.04\]. Further analyses showed that 1 and 10 mg/kg desipramine increased collection latencies compared to vehicle (*p* = 0.049 and *p* = 0.008, respectively). Accurate choice was not affected by desipramine \[Fig. [2b](#Fig2){ref-type="fig"}; *F*(3,39) = 0.31, *p* = 0.82\] or was the percentage of perseverative nose pokes after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(3,39) = 0.85, *p* = 0.48\]. Fig. 2The noradrenaline reuptake inhibitor desipramine decreases the percentage premature responses (**a**), does not affect the percentage correct choice (**b**), and increases both correct response latency (**c**) and the percentage omissions (**d**) in the 5CSRTT. All data are expressed as mean±SEM. \**p* \< 0.05 and \*\**p* \< 0.005 compared to vehicle treatment

Phenylephrine {#Sec12}
-------------

The α1-adrenoceptor agonist phenylephrine decreased the percentage of premature responses \[Fig. [3a](#Fig3){ref-type="fig"}; *F*(3,39) = 6.97, *p* = 0.001\] and this occurred only at the dose of 3.0 mg/kg compared to the vehicle (*p* \< 0.001). Phenylephrine also increased the latency to make a correct choice \[Fig. [3c](#Fig3){ref-type="fig"}; *F*(3,39) = 10.72, *ε* = 0.49, *p* = 0.002\] and increased the percentage of omissions \[Fig. [3d](#Fig3){ref-type="fig"}; *F*(3,39) = 4.77, *ε* = 0.55, *p* = 0.025\]. Further comparisons showed that 3.0 mg/kg phenylephrine significantly slowed response speed and increased omission rate compared to vehicle (*p* = 0.007 and *p* = 0.016, respectively). Moreover, phenylephrine significantly improved accurate choice \[Fig. [3b](#Fig3){ref-type="fig"}; *F*(3,39) = 2.92, *p* = 0.046\]. Further comparisons revealed that the high dose of 3.0 mg/kg phenylephrine tended to improve accurate choice compared to the vehicle, yet this effect did not reach statistical significance (*p* = 0.063). The percentage of perseverative nose pokes and latency to collect reward after correct choice were not altered by phenylephrine \[Table [1](#Tab1){ref-type="table"}; *F*(3,39) = 1.52, *p* = 0.22 and *F*(3,39) = 2.16, *ε* = 0.65, *p* = 0.14, respectively\]. Fig. 3The preferential α1-adrenoceptor and α2-adrenoceptor agonists phenylephrine and clonidide decrease the percentage premature responses (**a**, **e**), do not affect the percentage correct choice (**b**, **f**), and increase correct response latency (**c**, **g**) and the percentage omissions (**d**, **h**) in the 5CSRTT. All data are expressed as mean±SEM. \**p* \< 0.05 and \*\**p* \< 0.005 compared to vehicle treatment

Clonidine {#Sec13}
---------

The α2-adrenoceptor agonist clonidine reduced the percentage of premature responses \[Fig. [3e](#Fig3){ref-type="fig"}; *F*(2,26) = 8.47, *p* = 0.001\], and further analyses revealed that both doses decreased premature responding compared to vehicle (both *p* = 0.008). In addition, clonidine dose dependently lengthened the latency to make a correct response \[Fig. [3g](#Fig3){ref-type="fig"}; *F*(2,26) = 40.54, *p* \< 0.001\] at both doses compared to the vehicle (both *p* \< 0.001). Clonidine also dose dependently increased the percentage of omissions \[Fig. [3h](#Fig3){ref-type="fig"}; *F*(2,26) = 42.25, *p* \< 0.001\], and both doses increased omission rate compared to vehicle (both *p* \< 0.001). The percentage of perseverative responses after correct choice was significantly reduced by clonidine \[Table [1](#Tab1){ref-type="table"}; *F*(2,26) = 3.68, *p* = 0.039\]. Further analyses showed that only 0.03 mg/kg clonidine reduced the number of persevative nose pokes after correct choice compared to vehicle treatment (*p* = 0.031). Clonidine did neither affect accurate choice \[Fig. [3f](#Fig3){ref-type="fig"}; *F*(2,26) = 1.29, *p* = 0.29\] nor the latency to collect reward after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(2,26) = 1.40, *ε* = 0.63, *p* = 0.26\].

Isoprenaline {#Sec14}
------------

The non-selective β-adrenoceptor agonist isoprenaline reduced the percentage of premature responses \[Fig. [4a](#Fig4){ref-type="fig"}; *F*(3,39) = 3.98, *p* = 0.014\]. Further analyses showed that 0.3 mg/kg isoprenaline reduced premature responding compared to vehicle (*p* = 0.024). Isoprenaline dose dependently lengthened the latency to make a correct response \[Fig. [4c](#Fig4){ref-type="fig"}; *F*(3,39) = 17.11, *p* \< 0.001\] and further comparisons revealed that all doses lengthened the latency compared to the vehicle (0.1 and 1.0 mg/kg, both *p* \< 0.001 and 0.3 mg/kg, *p* = 0.002). The percentage of omissions was increased by isoprenaline \[Fig. [4d](#Fig4){ref-type="fig"}; *F*(3,39) = 6.80, *p* = 0.001\] at all doses compared to vehicle (0.1 mg/kg, *p* = 0.002; 0.3 mg/kg, *p* = 0.003 and 1.0 mg/kg, *p* \< 0.001). Furthermore, isoprenaline also lengthened the latency to collect reward after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(3,39) = 4.12, *ε* = 0.70, *p* = 0.026\], and this was only the case at 1.0 mg/kg compared to the vehicle (*p* = 0.023). Accurate choice \[Fig. [4b](#Fig4){ref-type="fig"}; *F*(3,39) = 1.04, *p* = 0.39\] and the percentage of perseverative responses after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(3,39) = 0.76, *p* = 0.53\] were not affected by isoprenaline. Fig. 4The non-selective β-adrenoceptor agonist isoprenaline decreases the percentage premature responses (**a**), does not affect the percentage correct choice (**b**), and increases correct response latency (**c**) and percentage of omissions (**d**) in the 5CSRTT. All data are expressed as mean±SEM. \**p* \< 0.05 and \*\**p* \< 0.005 compared to vehicle treatment

Dobutamine {#Sec15}
----------

Three animals were excluded from all analyses, as these individuals consistently omitted over 50 trials in all drug dose treatments including vehicle treatment. Challenges with the β1-adrenoceptor agonist dobutamine tended to decrease the percentage of premature responses, although the main dose effect did not reach statistical significance \[Fig. [5a](#Fig5){ref-type="fig"}; *F*(3,36) = 3.21, *ε* = 0.66, *p* = 0.059\]. Dobutamine did increase the percentage of omissions \[Fig. [5d](#Fig5){ref-type="fig"}; *F*(3,36) = 4.25, *p* = 0.011\] and further comparisons revealed that only 3 mg/kg dobutamine increased the omission rate compared to the vehicle (*p* = 0.002). In addition, dobutamine improved accurate choice \[Fig. [5b](#Fig5){ref-type="fig"}; *F*(3,36) = 4.14, *p* = 0.013\], and further analyses revealed that 6 mg/kg dobutamine improved visuospatial attention compared to the vehicle (*p* = 0.001). The latencies to make a correct choice \[Fig. [5c](#Fig5){ref-type="fig"}; *F*(3,36) = 2.06, *p* = 0.12\] and collect food reward after correct choice \[Table [1](#Tab1){ref-type="table"}; *F*(3,36) = 1.06, *ε* = 0.57, *p* = 0.36\] were not altered by dobutamine or was the percentage of perseverative responses \[Table [1](#Tab1){ref-type="table"}; *F*(3,36) = 1.53, *ε* = 0.47, *p* = 0.24\]. Fig. 5Effects of the β1 adrenoceptor agonist dobutamine and β2-adrenoceptor agonist clenbuterol on the percentage premature responses (**a**, **e**), percentage correct choice (**b**, **f**), correct response latency (**c**, **g**) and the percentage omissions (**d**, **h**) as measured in the 5CSRTT. Both dobutamine and clenbuterol improve visuospatial attention at doses that do not alter response latency or the percentage of omitted trials. In addition, clenbuterol exerts a beneficial effect on inhibitory response control by reducing the percentage premature responding. All data are expressed as mean±SEM. \**p* \< 0.05 and \*\**p* \< 0.005 compared to vehicle treatment

Clenbuterol {#Sec16}
-----------

One animal was excluded from all analyses due to a consistent high number of omissions during vehicle and drug treatments (\>50 trials). The administration of the selective β2-adrenoceptor agonist clenbuterol reduced the percentage of premature responses \[Fig. [5e](#Fig5){ref-type="fig"}; *F*(3,42) = 6.48, *ε* = 0.73, *p* = 0.004\], and further comparisons showed that all doses of clenbuterol decreased premature responding compared to vehicle (0.01 mg/kg, *p* = 0.036; 0.03 mg/kg, *p* = 0.008 and 0.1 mg/kg, *p* = 0.009). Likewise, clenbuterol lengthened the latency to make a correct response \[Fig. [5g](#Fig5){ref-type="fig"}; *F*(3,42) = 10.31, *ε* = 0.81, *p* \< 0.001\] at the 0.1 mg/kg dose compared to the vehicle (*p* \< 0.001). Clenbuterol also increased the percentage of omissions \[Fig. [5h](#Fig5){ref-type="fig"}; *F*(3,42) = 19.16, *ε* = 0.38, *p* \< 0.001\] and this also only occurred at the highest dose of 0.1 mg/kg compared to the vehicle (*p* = 0.001). Accurate choice was dose dependently improved by clenbuterol \[Fig. [5f](#Fig5){ref-type="fig"}; *F*(3,42) = 6.35, *p* = 0.001\], and both 0.03 and 0.1 mg/kg clenbuterol increased the percentage correct choice compared to vehicle (*p* = 0.002 and *p* = 0.005, respectively). The percentage of perseverative responses after correct choice and the latency to collect food reward were not affected by clenbuterol \[Table [1](#Tab1){ref-type="table"}; *F*(3,42) = 0.45, *p* = 0.72 and *F*(3,42) = 2.82, *ε* = 0.51, *p* = 0.094; respectively\].

Discussion {#Sec17}
==========

The present data are consistent with a functional role of noradrenergic transmission in inhibitory response control processes. In particular, the NA reuptake inhibitor desipramine was found to improve inhibitory response control at a dose that did not affect somatomotor activity. Likewise, methylphenidate seemed to have a similar effect at a low dose, whereas opposite effects were found at higher doses that impaired inhibitory response control by increasing premature responding. Both the selective α1-adrenoceptor and α2-adrenoceptor agonists (phenylephrine and clonidine) and the non-selective β-adrenoceptor agonist (isoprenaline) tested in the present study were found to alter inhibitory control, but these effects were only observed at doses that simultaneously increased response latencies and omission rate. By contrast, the selective β2-adrenoceptor agonist clenbuterol, and to a lesser extent the β1-agonist dobutamine, had beneficial effects on inhibitory control and visuospatial attention at doses that did not alter other behavioural parameters in the task.

The current findings with methylphenidate confirm earlier data indicating that methylphenidate increases impulsivity in the 5CSRTT (Milstein et al. [@CR40]; Navarra et al. [@CR43]; Puumala et al. [@CR49]; Van den Bergh et al. [@CR69]). Thus, in the present study, oral administration of 10 mg/kg methylphenidate also robustly increased premature responding. As methylphenidate increases monoamine neurotransmission by inhibiting the activity of monoamine transporter proteins (Rothman and Baumann [@CR55]), it has been well established that methylphenidate enhances both dopaminergic and noradrenergic transmission in corticostriatal brain regions (Gerasimov et al. [@CR29]; Kuczenski and Segal [@CR34]). In support of this, a large body of evidence has demonstrated that elevating dopamine (DA) signalling by means of the psychostimulant amphetamine or the selective DA reuptake inhibitor GBR12909 robustly increases premature responding in the 5CSRTT (Cole and Robbins [@CR22]; Harrison et al. [@CR30]; Pattij et al. [@CR48]; Van Gaalen et al. [@CR70]), possibly explaining the current observations with 10 mg/kg methylphenidate. By contrast, in the present study, a low oral dose of methylphenidate (1 mg/kg) tended to reduce the number of premature responses (*p* = 0.055). Interestingly, comparable low doses of methylphenidate have been shown to preferentially increase the extracellular levels of NA over DA in the prefrontal cortex and simultaneously improve sustained attention and working memory (Berridge et al. [@CR14]). This could explain the beneficial effect of the low dose methylphenidate on inhibitory control in the current study. Indeed, enhancing NA transmission by the NA reuptake inhibitor atomoxetine improves inhibitory response control both in humans (Chamberlain et al. [@CR20]) and laboratory animals (Bari et al. [@CR10]; Blondeau and Dellu-Hagedorn [@CR15]; Paterson et al. [@CR46]; Robinson et al. [@CR54]). In keeping with these findings, the selective NA transporter inhibitor desipramine also reduced the number of premature responses at 3 mg/kg without affecting other behavioural parameters in the 5CSRTT, although the effect size was smaller compared to the findings with atomoxetine in this same paradigm (Blondeau and Dellu-Hagedorn [@CR15]; Paterson et al. [@CR46]; Robinson et al. [@CR54]). Collectively, these data thus confirm the beneficial effects of elevating NA transmission on inhibitory response control in addition to other executive functions such as attentional set-shifting, behavioural flexibility and working memory (Berridge et al. [@CR14]; Lapiz et al. [@CR35]; Seu et al. [@CR61]) and this could underlie the therapeutic efficacy of atomoxetine and methylphenidate.

Given the results obtained with methylphenidate and desipramine, subsequent experiments were aimed at further exploring the possible contribution of α-adrenoceptors and β-adrenoceptors to modulate inhibitory response control. In this regard, previous work in rats and monkeys have implicated prefrontal cortical α2-adrenoceptor involvement in the beneficial effects of methylphenidate and atomoxetine on working memory (Arnsten and Dudley [@CR2]; Gamo et al. [@CR28]). To this aim, we tested the effects of phenylephrine, clonidine and isoprenaline. Whereas all of these compounds seemed effective in reducing premature responding, this only appeared to occur at doses that also strongly affected other behavioural parameters reflecting task performance, hampering a straightforward interpretation of these findings. Most prominently, the doses of these compounds reducing premature responding also increased the errors of omission and lengthened response latencies. These observations indicate that the effects on inhibitory response control may be secondary to general behavioural changes, e.g. somatomotor-suppressive effects or altered motivation. On the other hand, the observation that the highest dose isoprenaline increased the omissions and the response latencies but not premature responding might argue against such an interpretation. Our current findings are supported by previous studies, in which direct adrenoceptor agonists have been reported to lead to general behavioural alterations including lengthening of response latencies and increments in response omissions in instrumental behaviour (for example see, Jentsch et al. [@CR32]; Mair et al. [@CR36]; Marrs et al. [@CR38]). More relevant to our findings, the α2-adrenoceptor agonists dexmedetomidine and guanfacine were also found to decrease premature responding in the 5CSRTT at doses that simultaneously increased omission rates (Ruotsalainen et al. [@CR56]; Sirvio et al. [@CR64]) or lengthened latencies to collect food reward (Milstein et al. [@CR39]). Thus, consistent with these observations, a similar behavioural profile was obtained with clonidine in the current study. Although we did not test the lower doses of clonidine, previous work employing such lower doses in a different instrumental behaviour task reveals that the therapeutic window of this compound is narrow and associated with response rate suppressive effects (Dekeyne and Millan [@CR23]).

The beneficial effects of α2-adrenoceptor agonists such as clonidine and guanfacine on prefrontal cortical cognitive functions in preclinical as well as clinical models are thought to be primarily mediated through postsynaptic α2-adrenoceptor activation in the prefrontal cortex (Arnsten [@CR1]; Arnsten et al. [@CR3]). By contrast, presynaptic α2-adrenoceptor activation is well known to decrease NA transmission (for review see, Berridge and Waterhouse [@CR13]). In addition, α2-adrenoceptor agonists also have strong hypnotic/sedative effects that are presumably mediated in the basal forebrain, locus coeruleus and thalamus (e.g. Berridge and Foote [@CR12]; Buzsaki et al. [@CR18]; Mizobe et al. [@CR41]). Since all compounds were administered peripherally, it is at present difficult to disentangle the effects of clonidine on prefrontal cortical cognitive function from its somatomotor effects as this would require intracranial administration approach. Thus, while clonidine seemed to improve inhibitory response control consistent with earlier data (Milstein et al. [@CR39]; Ruotsalainen et al. [@CR56]; Sirvio et al. [@CR64]) and the clinical therapeutic efficacy of α2-adrenoceptor agonists (Arnsten et al. [@CR3]), central actions of clonidine on sedation/hypnosis are difficult to rule out. In contrast to the effects of clonidine on inhibitory response control, increasing activity at α2-adrenoceptors did not improve visuospatial attention contrasting earlier findings (Berridge et al. [@CR14]; Jentsch et al. [@CR32]; Paine et al. [@CR45]; Sagvolden [@CR57]). However, in the current study, animals were tested under standard task conditions with presumably "optimal" levels of attentional performance and noradrenergic tone. In this regard, there are indications that the beneficial effects of an elevated noradrenergic tone might particularly become apparent under conditions of poor performance or lower baseline noradrenergic tone (Jentsch and Anzivino [@CR31]; Jentsch et al. [@CR32]; Milstein et al. [@CR39]).

The effects of phenylephrine are partly in line with previous data demonstrating that the α1-adrenoceptor agonist St-587 improved both inhibitory response control and visuospatial attention (Puumala et al. [@CR50]). These beneficial effects of St-587 on visuospatial attention and not inhibitory response control could be antagonized by the α1-adrenoceptor antagonist prazosin. This suggests particular involvement of these receptor subtypes in attention, for instance by their role in increasing vigilance (Sirvio and MacDonald [@CR63]) and is consistent with the view that α1-adrenoceptor activation enhances the signal-to-noise ratio and tunes processing of sensory information through subcortical and sensory cortical regions (for reviews see, Arnsten [@CR1]; Berridge and Waterhouse [@CR13]). Accordingly, phenylephrine improved accurate choice, albeit separate post hoc comparisons on the high-dose phenylephrine (3.0 mg/kg) failed to reach statistical significance (*p* = 0.063). The effects of phenylephrine on premature responding occurred in concert with effects on response latencies and omission rate and may therefore will be secondary to its effects on somatomotor activity.

In addition to the well-known involvement of β-adrenoceptors in memory consolidation processes (for review see, Sara [@CR58]), until now few studies have examined the role of these receptors in executive cognitive functioning, namely working memory. Inasmuch one can draw conclusions from these initial studies, they suggest an opposing modulatory role of β1-adrenoceptors and β2-adrenoceptors in working memory. While a β1-adrenoceptor agonist deteriorates working memory (Ramos et al. [@CR51]), a β2-adrenoceptor agonist was found to improve working memory performance (Ramos et al. [@CR52]). Interestingly, recent work showed that the non-selective β-adrenoceptor antagonist propanolol attenuated the detrimental effects of methylphenidate on premature responding in the 5CSRTT (Milstein et al. [@CR40]). This suggests that methylphenidate impairs inhibitory response control partly through β-adrenoceptor activation at a dose elevating both NA and DA transmission. To our knowledge, the present study is the first reporting on the behavioural effects of β-adrenoceptor agonists in the 5CSRTT.

Whereas the non-selective β-adrenoceptor agonist isoprenaline did reduce premature responding at 0.3 mg/kg, this same dose simultaneously increased omission rate and response latencies comparable to the effects of the α-adrenoceptor agonists hampering a straightforward interpretation of these data. Importantly, the present data indicate that clenbuterol, a preferential β2-adrenoceptor agonist with approximately tenfold higher affinity for β2-adrenoceptors over β1-adrenoceptors (Baker [@CR8]), dose dependently decreased premature responding at doses that did not significantly alter the measures of somatomotor activity. Moreover, in contrast to the high-dose clenbuterol, the intermediate 0.03 mg/kg dose improved visuospatial attention by increasing accurate choice without simultaneous deteriorative effects on omissions or response latencies (Fig. [5f](#Fig5){ref-type="fig"}). Thus, in extension to beneficial effects on working memory (Ramos et al. [@CR52]), enhancing the tone at β2-adrenoceptors also improved inhibitory response control. An important point of consideration is that in addition to the beneficial behavioural effects of particularly clenbuterol observed here, β2-adrenoceptors and also β1-adrenoceptors are heavily implicated in cardiac function (Brodde and Michel [@CR16]). Indeed, clenbuterol has been shown to exert myotoxic and potent haemodynamic effects in rats starting at doses of 0.1 mg/kg (Burniston et al. [@CR17]; Sillence et al. [@CR62]). Although in the current study, lower doses of clenbuterol were employed (0.01 and 0.03 mg/kg) we cannot entirely rule out that these same doses affected cardiac function.

Similar to clenbuterol, the β1-adrenoceptor agonist dobutamine increased visuospatial attention. Nonetheless, this effect was only observed at the highest dose of 6.0 mg/kg. Although dobutamine has an approximately tenfold higher affinity for β1-adrenoceptors over β2-adrenoceptors (Williams and Bishop [@CR72]), it is possible that at this dose the beneficial effects of this drug on visuospatial attention are mediated through β2-adrenoceptor activation (Baker [@CR8]; Makhay and O'Donnell [@CR37]). At the same time, it should be noted that these beneficial effects on attention were not accompanied by significant improvements of inhibitory control. Thus, whereas β1-adrenoceptor activation was previously found to impair working memory (Ramos et al. [@CR51]), we did not find evidence for similar effects on attention and inhibitory response control. Collectively, the observation that dobutamine and clenbuterol improved visuospatial attention is consonant with the notion that similar to α1-adrenoceptor activation (see above), enhancing β-adrenoceptor activity tunes information processing presumably via subcortical and sensory cortical mechanisms (Arnsten [@CR1]; Berridge and Waterhouse [@CR13]).

Our understanding of the contribution of different β-adrenoceptors in inhibitory response control is limited as yet. Altogether, the present experiments with β-adrenoceptor agonists further strengthen the notion of β2-adrenoceptor and to a lesser extent β1-adrenoceptor improvement of prefrontal executive function and in particular inhibitory response control and visuospatial attention. In this respect, it is of interest to note that intracranial clenbuterol injections into the prefrontal cortex ameliorated working memory performance in rats implicating a functional role for β2-adrenoceptors in this brain region in prefrontal function (Ramos et al. [@CR52]). The current observations with β-adrenoceptor agonists are somewhat at odds with the single other study in this area reporting that propanolol attenuates the detrimental effects of methylphenidate on inhibitory response control (Milstein et al. [@CR40]). Evidence from that study suggests subcortical β-adrenoceptor modulation of DA in the effects of methylphenidate, since cortical NA depletion did not attenuate the effects methylphenidate. Clearly, future studies including the effects of selective β-adrenoceptor antagonists and employing intracranial approaches are warranted to further unravel this.

In summary, the present data extend previous findings and show that indirect as well as direct adrenoceptor agonists improve inhibitory response control in the 5CSRTT. Although the observed inhibitory effects of most direct α-adrenoceptor and β-adrenoceptor agonists on impulsive action cannot be interpreted unambiguously, our findings with the β2-adrenoceptor agonist clenbuterol---and to a lesser extent the β1-adrenoceptor agonist dobutamine---are consistent with a prominent role of noradrenergic neurotransmission in inhibitory response control. This corroborates the notion that the central noradrenergic system is involved in optimizing behavioural responses including executive cognitive functioning (for reviews, see, e.g. Aston-Jones and Cohen [@CR6]; Sara [@CR58]) and particularly points to a role of β2-adrenoceptors therein.
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